Safety of anacetrapib in patients with or at high risk for coronary heart disease.
By C. Cannon, Sukrut Shah, H. Dansky, M. Davidson, E. Brinton, A. Gotto, M. Stepanavage, S. Liu, Patrice H. Gibbons, T. B. Ashraf and 3 more. New England Journal of Medicine, 2010
713 citations recorded by the source corpus.
Subfields: Cancer Research, Endocrinology, Diabetes and Metabolism, Surgery
View Paper: https://www.semanticscholar.org/paper/6b83e869844c40a05507d532a6602427cce71b40
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
- Børge G. Nordestgaard
- Jan Boren
- Sekar Kathiresan
- Marja-Riitta Taskinen
- Eric Boerwinkle
- I. Tabas
- S. Grundy
- Thomas Breslin
In Endocrinology, Diabetes and Metabolism
- Børge G. Nordestgaard
- A. Tybjærg-Hansen
- Jan Boren
- Marja-Riitta Taskinen
- S. Grundy
- L. Tokgözoğlu
- I. Tabas
- E. Rimm
In Surgery
- Børge G. Nordestgaard
- A. Tybjærg-Hansen
- Jan Boren
- Sekar Kathiresan
- Marja-Riitta Taskinen
- S. Grundy
- L. Tokgözoğlu
- I. Tabas
Citations in the corpus
- Metabolic syndrome update. (2016, background): “[100] Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, et al.”
- Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study (2012, background): “33 As such, whether the protection aff orded by the CETP variant is due to the change in HDL or LDL cholesterol is diffi cult to distinguish.”
- Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management (2011, background): “the off-target effects associated with torcetrapib, as indicated by recent studies.(235,236) Clinical outcome data from ongoing or”
- The Cellular Biology of Macrophages in Atherosclerosis (2011, positive): “Although an initial trial in this area showed disappointing results, possibly due to off-target effects, the early results of a second CETP inhibitor trial appear promising (Cannon et al., 2010).”